BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression

Virchows Archiv

Volumn 461, Issue 3, 2012, Pages 305-312

  Bal, Amanjit ^a   Verma, Sangeeta ^a   Joshi, Kusum ^a   Singla, Anuj ^a   Thakur, Ravi ^a   Arora, Sunil ^a   Singh, Gurpreet ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Basal like breast cancer; BRCA1; Sporadic breast cancer; Triple negative breast cancer

Indexed keywords

BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER CLASSIFICATION; CANCER PROGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DRUG TARGETING; FAMILIAL CANCER; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDIA; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SPORADIC BREAST CANCER; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84867404228     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1286-z     Document Type: Article

References (33)

1. Easton DF, Bishop DT, Ford D (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52:678-701 (Pubitemid 23310135)
2. Claus EB, Schildkraut JM, Thompson WD (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318-2324 (Pubitemid 26162426)
3. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122 (Pubitemid 24345332)
4. Lancaster JM, Wooster R, Mangion J et al (1996) BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13:238-240 (Pubitemid 26000445)
5. Johnson SM, Shaw JA, Walker RA (2002) Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer 98:205-209 (Pubitemid 34150803)
6. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054 (Pubitemid 37448928)
7. Kim MJ, Ro JY, Ahn SH et al (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum Pathol 37:1217-1226 (Pubitemid 44286991)
8. DeVargas RL, Michor F (2011) Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis. J Theor Biol 273:207-215
9. Valentin MD, Da Silva SD, Privat M, Alaoui-Jamali M, Bignon YB (2012) Molecular insights on basal-like breast cancer. Breast Canc Res Treat 2012 Jan 11 [Epub ahead of print]
10. Santarosa M, Maestro R (2012) BRACking news on triplenegative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. Cancer Metastasis Rev 31:131-142
11. Warmoes M, Jaspers JE, Pham TV et al (2012) Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics 2012 Feb. 24 [Epub ahead of print]
12. Da Pang, Zhao Y, Xue W et al (2011) Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese. Med Oncol 2011 Nov. 11 [Epub ahead of print]
13. Ibragimova I, Cairns P (2011) Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Meth Mol Biol 780:277-291
14. Jaspers JE, Rottenberg S, Jonkers J (2009) Therapeutic options for triple negative breast cancers with defective homologous recombination. Biochim Biophys Acta 1796:266-280
15. Tutt A, Robson M, Garber JE et al (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof of-concept trial. Lancet 376:235-244
16. Taylor J, Lymboura M, Pace PE et al (1998) An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer 79:334-342 (Pubitemid 28359729)
17. Rakha EA, El-Sheikh SE, Kandil MA et al (2008) Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 39:857-865
18. Lambie H, Miremadi A, Pinder SE et al (2003) Prognostic significance of BRCA1 expression in sporadic breast carcinomas. J Pathol 200:207-213 (Pubitemid 36748029)
19. Nielsen TO, Hsu FD, Jensen K (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374 (Pubitemid 39100473)
20. Abd El-Rehim DM, Pinder SE, Paish CE (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203:661-671 (Pubitemid 38714103)
21. Foulkes WD, Ingunn MS, Chappuis PO et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:19
22. Singha AK, Pandey A, Tewarib M, Shukla HS, Pandey HP (2011) Epigenetic silencing of BRCA1 gene associated with demographic and pathologic factors in sporadic breast cancer: a study of an Indian population. Eur J Cancer Prev 20:478-483
23. Ben GR, Hachana M, Ziadi S et al (2011) Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients. Canc Epidemiol Oct. 4, (Epub ahead of print)
24. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428 (Pubitemid 34587077)
25. Birgisdottir V, Stefansson OA (2006) Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 8:R38
26. Foulkes WD, Stefansson IM, Chappuis PO et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485 (Pubitemid 37279334)
27. Esteller M (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21:5427-5440 (Pubitemid 34983479)
28. Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107-116 (Pubitemid 43361543)
29. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569 (Pubitemid 30212318)
30. Xu CF, Brown MA, Chambers JA et al (1995) Distinct transcription start sites generate two forms of BRCA1 mRNA. Hum Mol Genet 4:2259-2264
31. Catteau A, Morris JR (2002) BRCA1 methylation: a significant role in tumour development? Semin Cancer Biol 12:359-371
32. Mirza S, Sharma G, Prasad CP et al (2007) Promoter hypermethylation of TMS1, BRCA1, ERá and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 81:280-287 (Pubitemid 47030571)
33. Raju Bagadi SA, Prasad CP, Kaur J et al (2008) Clinical significance of promoter hypermethylation of RASSF1A, RARβ2, BRCA1 and HOXA5 in breast cancers of Indian patients. Life Sci 82:1288-1292